Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the safety and efficacy of preservative-free (PF) latanoprost in glaucoma patients. Methods: In this prospective, open-label, observational study, a total of 27 primary open-angle glaucoma patients who usedbenzalkonium chloride-preserved prostaglandin analogues for at least 6 months were enrolled. After changing the eye dropsto PF lataprost, the intraocular pressure (IOP) and ocular surface symptoms and signs were evaluated in all patients on days 0(first visit, D0), 45 (D45), and 90 (D90). Results: Mean IOP remained stable during the study period (14.0 ± 2.4 mmHg at D0, 13.9 ± 2.0 mmHg at D45, 13.7 ± 2.2mmHg at D90; p = 0.603). Mean deviation, pattern standard deviation, and best-corrected visual acuity were similar beforeand after eye drops replacement. Bulbar conjunctival hyperemia, corneal staining, and conjunctival staining were significantlydecreased over 90 days (p = 0.025, p < 0.001, p = 0.020, respectively). The ocular surface disease index score showed a statisticallysignificant improvement from 26.4 ± 18.5 at D0 to 19.8 ± 17.0 at D45 and 15.7 ± 15.6 at D90 (p < 0.001). In the evaluationof ocular tolerability, burning symptoms and dryness were significantly decreased (p = 0.001, p = 0.040). Conclusions: The effects of PF latanoprost on reducing IOP were comparable with those of benzalkonium chloride-preservedprostaglandin analogues, but side effects on the ocular surface were much less pronounced when PF latanoprost was used. With this efficacy, PF latanoprost could slow the progression of glaucoma by increasing patient compliance.
Abstract
Purpose: To evaluate the safety and efficacy of preservative-free (PF) latanoprost in glaucoma patients. Methods: In this prospective, open-label, observational study, a total of 27 primary open-angle glaucoma patients who usedbenzalkonium chloride-preserved prostaglandin analogues for at least 6 months were enrolled. After changing the eye dropsto PF lataprost, the intraocular pressure (IOP) and ocular surface symptoms and signs were evaluated in all patients on days 0(first visit, D0), 45 (D45), and 90 (D90). Results: Mean IOP remained stable during the study period (14.0 ± 2.4 mmHg at D0, 13.9 ± 2.0 mmHg at D45, 13.7 ± 2.2mmHg at D90; p = 0.603). Mean deviation, pattern standard deviation, and best-corrected visual acuity were similar beforeand after eye drops replacement. Bulbar conjunctival hyperemia, corneal staining, and conjunctival staining were significantlydecreased over 90 days (p = 0.025, p < 0.001, p = 0.020, respectively). The ocular surface disease index score showed a statisticallysignificant improvement from 26.4 ± 18.5 at D0 to 19.8 ± 17.0 at D45 and 15.7 ± 15.6 at D90 (p < 0.001). In the evaluationof ocular tolerability, burning symptoms and dryness were significantly decreased (p = 0.001, p = 0.040). Conclusions: The effects of PF latanoprost on reducing IOP were comparable with those of benzalkonium chloride-preservedprostaglandin analogues, but side effects on the ocular surface were much less pronounced when PF latanoprost was used. With this efficacy, PF latanoprost could slow the progression of glaucoma by increasing patient compliance.
참고문헌 (22)
- Tham YC, "Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis", Ophthalmology, 121, pp.2081~2090 (2014)
- Kim CS, "Prevalence of primary open-angle glaucoma in central South Korea the Namil study", Ophthalmology, 118, pp.1024~1030 (2011)
- Ji Hyun Kim, "Prevalence and Characteristics of Glaucoma among Korean Adults", Korean Journal of Ophthalmology, 25(2), pp.110~115 (2011), 대한안과학회
- Kim KE, "Prevalence, awareness, and risk factors of primary open-angle glaucoma: Korea National Health and Nutrition Examination Survey 2008-2011", Ophthalmology, 123, pp.532~541 (2016)
- Lee AJ, "Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension", Clin Ophthalmol, 4, pp.741~764 (2010)
- Tomic M, "Influence of BAK-preserved prostaglandin analog treatment on the ocular surface health in patients with newly diagnosed primary open-angle glaucoma", Biomed Res Int, 2013, pp.603782~ (2013)
- El Hajj Moussa WG, "Comparison of efficacy and ocular surface disease index score between bimatoprost, latanoprost, travoprost, and tafluprost in glaucoma patients", J Ophthalmol, 2018, pp.1319628~ (2018)
- Uusitalo H, "Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials", Clin Ophthalmol, 10, pp.445~454 (2016)
- 최진아, "녹내장의 최신 치료 안약", 대한의사협회지, 62(9), pp.497~504 (2019), 대한의사협회
- van der Worp E, "Evaluation of signs and symptoms in 3- and 9-o’clock staining", Optom Vis Sci, 86, pp.260~265 (2009)
- Begley C, "Review and analysis of grading scales for ocular surface staining", Ocul Surf, 17, pp.208~220 (2019)
- Cho P, "Tear break-up time: clinical procedures and their effects", Ophthalmic Physiol Opt, 18, pp.319~324 (1998)
- Charnock C, "Are multidose over-the-counter artificial tears adequately preserved?", Cornea, 25, pp.432~437 (2006)
- Baudouin C, "Preservatives in eyedrops:the good, the bad and the ugly", Prog Retin Eye Res, 29, pp.312~334 (2010)
- Boimer C, "Preservative exposure and surgical outcomes in glaucoma patients: the PESO study", J Glaucoma, 22, pp.730~735 (2013)
- Misiuk-Hojlo M, "The RELIEF study: tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension", Eur J Ophthalmol, 29, pp.210~215 (2019)
- 박지혜, "벤잘코니움의 장기 노출이 섬유주세포의 노화에 미치는 영향", 대한안과학회지, 60(1), pp.55~61 (2019), 대한안과학회
- Garcia-Feijoo J, "Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost", Clin Ophthalmol, 10, pp.2085~2091 (2016)
- Tokuda N, "Changes in ocular surface characteristics after switching from benzalkonium chloride-preserved latanoprost to preservative-free tafluprost or benzalkonium chloride-preserved tafluprost", J Ophthalmol, 2017, pp.3540749~ (2017)
- 이송민, "경도에서 중등도의 안구건조증을 가진 정상안압녹내장에서 무보존제 라타노프로스트의 임상효과", 대한안과학회지, 61(6), pp.639~644 (2020), 대한안과학회
- Kim YW, "Efficacy and patient tolerability of preservative-free latanoprost in Korean primary open angle glaucoma patients", J Korean Glaucoma Soc, 9, pp.10~16 (2020)
- Lee W, "Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study", BMC Ophthalmol, 17, pp.61~ (2017)